Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. COLLAGEN TYPE III DEGRADATION IS ASSOCIATED WITH DETERIORATION OF KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WITH MICROALBUMINURIA.

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Coronary arterial calcification, abdominal aortic calcification, and pulse wave velocity in dialysis patients

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Decreases in weight with bardoxolone methyl in obese patients with chronic kidney disease stage 4 and type 2 diabetes - post-hoc analyses from beacon

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  1. Increased risk of Staphylococcus aureus bacteremia in hemodialysis-A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The impact of hemodialysis on mortality risk and cause of death in Staphylococcus aureus endocarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of Infective Endocarditis in Patients with End Stage Renal Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effect of Reduced Renal Function on Time in Therapeutic Range Among Anticoagulated Atrial Fibrillation Patients

    Research output: Contribution to journalLetterResearchpeer-review

View graph of relations

An earlier controlled trial showed that over an average of 26 months, enalapril slowed the progression of chronic renal failure. Following completion of the trial, the patients continued to receive antihypertensive treatment according to ordinary clinical criteria. All but four patients in the enalapril group remained on that drug, and two patients in the control group were switched to an angiotensin-converting enzyme (ACE) inhibitor. In the present study the fate of the 70 patients 44 months after termination of the trial was investigated, with a total follow-up of around 7 years. In the original enalapril group, 12 of the 35 patients (34%) were alive without renal replacement therapy versus five of the 35 patients (14%) in the control group. This difference of 20% in favour of having been in the enalapril group in the original trial was significant (P = 0.05; 95% confidence limits 0.5-39.5%). The influence of baseline proteinuria on clinical outcome was analysed. In the original control group, baseline renal clearances of albumin (Calb) and immunoglobulin G (CIgG) were significantly lower in patients surviving without renal replacement therapy at follow-up than in patients who ultimately developed end-stage renal failure (ESRF) (P < 0.05). In the original enalapril group, these baseline clearances were equal in the two renal outcome groups. In all patients, baseline Calb and CIgG were negatively correlated with the rate of change in GFR during the controlled trial (r = -0.37, P < 0.01 and r = -0.28, P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Original languageEnglish
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Volume10
Issue number7
Pages (from-to)1182-8
Number of pages7
ISSN0931-0509
Publication statusPublished - 1995

    Research areas

  • Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Enalapril, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Lipids, Male, Middle Aged, Proteinuria, Sex Characteristics, Survival Analysis, Treatment Outcome

ID: 44947702